| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 22.44M | 9.89M | 9.93M | 30.02M | 652K | 1.66M | 5.72M |
| Revenue Growth % | - | -0.56% | 0% | 2.02% | -0.98% | 1.54% | 2.45% |
| Cost of Goods Sold | 24.81M | 29.22M | 37.48M | 1.38M | 0 | 4.04M | 0 |
| COGS % of Revenue | 1.11% | 2.96% | 3.77% | 0.05% | - | 2.44% | - |
| Gross Profit | -2.37M | -19.33M | -27.55M | 28.64M | 652K | -2.38M | 5.72M |
| Gross Margin % | -0.11% | -1.96% | -2.77% | 0.95% | 1% | -1.44% | 1% |
| Gross Profit Growth % | - | -7.17% | -0.43% | 2.04% | -0.98% | -4.66% | 3.4% |
| Operating Expenses | 28.59M | 5.74M | 9.38M | 73.91M | 103.98M | 89.57M | 86.29M |
| OpEx % of Revenue | 1.27% | 0.58% | 0.94% | 2.46% | 159.48% | 54.06% | 15.08% |
| Selling, General & Admin | 3.78M | 5.74M | 9.38M | 18.72M | 21.08M | 19.3M | 19.08M |
| SG&A % of Revenue | 0.17% | 0.58% | 0.94% | 0.62% | 32.33% | 11.65% | 3.33% |
| Research & Development | 24.81M | 29.22M | 37.48M | 56.56M | 82.9M | 74.31M | 67.21M |
| R&D % of Revenue | 1.11% | 2.96% | 3.77% | 1.88% | 127.15% | 44.85% | 11.75% |
| Other Operating Expenses | -357K | -29.22M | -37.48M | -1.38M | 0 | -4.04M | 0 |
| Operating Income | -6.15M | -25.07M | -36.93M | -45.27M | -103.33M | -91.96M | -80.57M |
| Operating Margin % | -0.27% | -2.54% | -3.72% | -1.51% | -158.48% | -55.5% | -14.08% |
| Operating Income Growth % | - | -3.08% | -0.47% | -0.23% | -1.28% | 0.11% | 0.12% |
| EBITDA | -5.89M | -24.53M | -36.31M | -43.89M | -100.26M | -87.92M | -76.74M |
| EBITDA Margin % | -0.26% | -2.48% | -3.66% | -1.46% | -153.77% | -53.06% | -13.41% |
| EBITDA Growth % | - | -3.16% | -0.48% | -0.21% | -1.28% | 0.12% | 0.13% |
| D&A (Non-Cash Add-back) | 255K | 537K | 618K | 1.38M | 3.07M | 4.04M | 3.83M |
| EBIT | -4.76M | -25.07M | -36.93M | -45.27M | -103.33M | -91.96M | -80.57M |
| Net Interest Income | -1.67M | 1.18M | 549K | 625K | 1.59M | 4.67M | 5.17M |
| Interest Income | 966K | 1.18M | 549K | 625K | 1.59M | 4.67M | 5.17M |
| Interest Expense | 2.63M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.24M | 1.08M | 328K | 295K | 1.38M | 4.66M | 5.16M |
| Pretax Income | -7.39M | -23.98M | -36.6M | -44.97M | -101.94M | -87.3M | -75.41M |
| Pretax Margin % | -0.33% | -2.43% | -3.68% | -1.5% | -156.36% | -52.68% | -13.18% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -7.39M | -23.98M | -36.6M | -44.97M | -101.94M | -87.3M | -75.41M |
| Net Margin % | -0.33% | -2.43% | -3.68% | -1.5% | -156.36% | -52.68% | -13.18% |
| Net Income Growth % | - | -2.25% | -0.53% | -0.23% | -1.27% | 0.14% | 0.14% |
| Net Income (Continuing) | -7.39M | -23.98M | -36.6M | -44.97M | -101.94M | -87.3M | -75.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.49 | -0.57 | -0.88 | -1.07 | -2.41 | -2.05 | -1.49 |
| EPS Growth % | - | -0.16% | -0.54% | -0.22% | -1.25% | 0.15% | 0.27% |
| EPS (Basic) | -0.49 | -0.57 | -0.88 | -1.07 | -2.41 | -2.05 | -1.49 |
| Diluted Shares Outstanding | 15.04M | 41.74M | 41.77M | 42.03M | 42.38M | 42.6M | 50.76M |
| Basic Shares Outstanding | 15.04M | 41.74M | 41.77M | 42.03M | 42.38M | 42.6M | 50.76M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 65.63M | 42.44M | 345.64M | 288.27M | 184.58M | 143.22M | 79.22M |
| Cash & Short-Term Investments | 60.38M | 39.09M | 335.45M | 268.8M | 161.28M | 130.63M | 72.99M |
| Cash Only | 31.64M | 7.01M | 157.9M | 92.27M | 47.38M | 125.63M | 57.39M |
| Short-Term Investments | 28.73M | 32.07M | 177.55M | 176.54M | 113.9M | 5M | 15.6M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 23.3M | 12.6M | 6.23M |
| Total Non-Current Assets | 2.53M | 2.53M | 3.35M | 10.32M | 20.74M | 16.34M | 11.83M |
| Property, Plant & Equipment | 2.5M | 2.44M | 3M | 9.94M | 17.67M | 13.8M | 9.81M |
| Fixed Asset Turnover | 8.96x | 4.06x | 3.31x | 3.02x | 0.04x | 0.12x | 0.58x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 23K | 90K | 349K | 381K | 3.07M | 2.54M | 2.02M |
| Total Assets | 68.16M | 44.97M | 348.99M | 298.58M | 205.32M | 159.56M | 91.05M |
| Asset Turnover | 0.33x | 0.22x | 0.03x | 0.10x | 0.00x | 0.01x | 0.06x |
| Asset Growth % | - | -0.34% | 6.76% | -0.14% | -0.31% | -0.22% | -0.43% |
| Total Current Liabilities | 20.85M | 19.98M | 16.83M | 24.59M | 24.96M | 11.45M | 8.92M |
| Accounts Payable | 2.05M | 3.05M | 1.75M | 10.01M | 7.17M | 1.59M | 2.42M |
| Days Payables Outstanding | 30.13 | 38.11 | 17.08 | 2.65K | - | 143.31 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 983K | 3.07M | 5.8M | 11.25M | 5.84M | 4.83M | 5.6M |
| Current Ratio | 3.15x | 2.12x | 20.53x | 11.72x | 7.39x | 12.51x | 8.88x |
| Quick Ratio | 3.15x | 2.12x | 20.53x | 11.72x | 7.39x | 12.51x | 8.88x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 58.39M | 59.53M | 22.29M | 2.21M | 4.2M | 3.41M | 2.51M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 4.2M | 3.41M | 2.51M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 50M | 49.96M | 987K | 2.21M | 0 | 0 | 0 |
| Total Liabilities | 79.24M | 79.52M | 39.13M | 26.8M | 29.17M | 14.86M | 11.42M |
| Total Debt | 0 | 0 | 0 | 0 | 4.9M | 4.2M | 3.41M |
| Net Debt | -31.64M | -7.01M | -157.9M | -92.27M | -42.48M | -121.42M | -53.98M |
| Debt / Equity | - | - | - | - | 0.03x | 0.03x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -2.34x | - | - | - | - | - | - |
| Total Equity | -11.08M | -34.55M | 309.86M | 271.79M | 176.16M | 144.71M | 79.63M |
| Equity Growth % | - | -2.12% | 9.97% | -0.12% | -0.35% | -0.18% | -0.45% |
| Book Value per Share | -0.74 | -0.83 | 7.42 | 6.47 | 4.16 | 3.40 | 1.57 |
| Total Shareholders' Equity | -11.08M | -34.55M | 309.86M | 271.79M | 176.16M | 144.71M | 79.63M |
| Common Stock | 1K | 1K | 5K | 5K | 5K | 5K | 5K |
| Retained Earnings | -11.51M | -35.49M | -72.09M | -117.07M | -219.01M | -306.31M | -381.72M |
| Treasury Stock | 0 | -887K | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -49.06M | 54K | -63K | -560K | -877K | 4K | 2K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.9M | -20.98M | -33.66M | -57.12M | -94.5M | -81.23M | -60.52M |
| Operating CF Margin % | -0.31% | -2.12% | -3.39% | -1.9% | -144.94% | -49.02% | -10.58% |
| Operating CF Growth % | - | -2.04% | -0.6% | -0.7% | -0.65% | 0.14% | 0.25% |
| Net Income | -7.39M | -23.98M | -36.6M | -44.97M | -101.94M | -87.3M | -75.41M |
| Depreciation & Amortization | 255K | 537K | 618K | 1.38M | 3.07M | 4.04M | 3.83M |
| Stock-Based Compensation | 425K | 461K | 1.27M | 5.47M | 6.46M | 6.94M | 9.55M |
| Deferred Taxes | -404K | 0 | 1K | 3.04M | 0 | 0 | 0 |
| Other Non-Cash Items | 2.71M | -207K | 89K | 1.52M | 2.38M | -816K | -1.5M |
| Working Capital Changes | -2.5M | 2.22M | 970K | -23.55M | -4.46M | -4.09M | 3.02M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.12M | 1M | -1.75M | 7.87M | -2.84M | -5.63M | 832K |
| Cash from Investing | -29.93M | -3.59M | -146.32M | -10.44M | 49.44M | 110.86M | -8.51M |
| Capital Expenditures | -1.18M | -470K | -727K | -7.93M | -11.61M | -407K | -59K |
| CapEx % of Revenue | 0.05% | 0.05% | 0.07% | 0.26% | 17.81% | 0.25% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -15K | 0 | -145.59M | -2.52M | 0 | 0 | 0 |
| Cash from Financing | 35.15M | -64K | 330.87M | 1.93M | 171K | 48.62M | 787K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | -152K | -64K | -19.05M | 0 | 0 | -53K | 804K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -8.08M | -21.45M | -34.39M | -65.04M | -106.11M | -81.64M | -60.57M |
| FCF Margin % | -0.36% | -2.17% | -3.46% | -2.17% | -162.75% | -49.27% | -10.59% |
| FCF Growth % | - | -1.65% | -0.6% | -0.89% | -0.63% | 0.23% | 0.26% |
| FCF per Share | -0.54 | -0.51 | -0.82 | -1.55 | -2.50 | -1.92 | -1.19 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.87x | 0.92x | 1.27x | 0.93x | 0.93x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -26.59% | -15.46% | -45.52% | -54.41% | -67.23% |
| Return on Invested Capital (ROIC) | - | - | -50.18% | -20.48% | -49.49% | -87.88% | -247.01% |
| Gross Margin | -10.54% | -195.52% | -277.32% | 95.4% | 100% | -143.93% | 100% |
| Net Margin | -32.92% | -242.56% | -368.46% | -149.83% | -15635.74% | -5268.44% | -1318.13% |
| Debt / Equity | - | - | - | - | 0.03x | 0.03x | 0.04x |
| Interest Coverage | -2.34x | - | - | - | - | - | - |
| FCF Conversion | 0.93x | 0.87x | 0.92x | 1.27x | 0.93x | 0.93x | 0.80x |
| Revenue Growth | - | -55.94% | 0.48% | 202.16% | -97.83% | 154.14% | 245.26% |
| 2024 | |
|---|---|
| License | 3.4M |
| License Growth | - |
Shattuck Labs, Inc. (STTK) reported $1.0M in revenue for fiscal year 2024. This represents a 96% decrease from $22.4M in 2018.
Shattuck Labs, Inc. (STTK) grew revenue by 245.3% over the past year. This is strong growth.
Shattuck Labs, Inc. (STTK) reported a net loss of $54.9M for fiscal year 2024.
Shattuck Labs, Inc. (STTK) has a return on equity (ROE) of -67.2%. Negative ROE indicates the company is unprofitable.
Shattuck Labs, Inc. (STTK) had negative free cash flow of $48.8M in fiscal year 2024, likely due to heavy capital investments.